FDA extends review period for Ascendis Pharma's first drug

Ascendis Pharma has to wait three more months for the FDA to give its verdict on the firm's drug lonapegsomatropin for treating pediatric growth hormone deficiency.

Photo: Kevin Grønnemann

Just two weeks before the deadline, the US Food and Drug Administration (FDA) has extended the review period for Ascendis Pharma's first drug candidate lonapegsomatropin, according to an Ascendis Pharma press release.

Now, the FDA must make a decision on lonapegsomatropin, also known as Transcon hgh, by Sept. 25, which is a three-month extension in total.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs